NTLA Crosses Above Average Analyst Target
October 04, 2017 at 09:21 AM EDT
In recent trading, shares of Intellia Therapeutics Inc (NTLA) have crossed above the average analyst 12-month target price of $28.60, changing hands for $30.52/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..